The Prevalence of Factor V Arg³⁰⁶→Thr (Factor V Cambridge) and Factor V Arg³⁰⁶→Gly Mutations in Different Human Populations

• References

• 1 Dählback B. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol 1997; 34: 217-34.
• 2 Bertina RM, Koeleman PC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 3 Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg³⁰⁶→Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-4.
• 4 Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91: 1135-9.
• 5 Rees DC, Cos M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
• 6 Franco RF, Araújo AG, Guerreiro JF, Elion J, Zago MA. Analysis of the 677 C→T mutation in the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost 1998; 79: 119-21.
• 7 Franco RF, Santos SEB, Elion J, Tavella MH, Zago MA. The prevalence of the G20210A polymorphism in the 3’- untranslated region of the prothrombin gene in different human populations. Acta Haematologica 1998; 100: 9-12.
• 8 Rosendaal F, Doggen C, Zivelin A, Arruda V, Aiach M, Siscovick D, Hillarp A, Watzke H, Bernardi F, Cumming A, Preston F, Reitsma P. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-8.
• 9 Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-7.
• 10 Franco RF, Maffei FH, Lourenço D, Morelli V, Thomazini IA, Piccinato CE, Tavella MH, Zago MA. Factor V Arg³⁰⁶→Thr (factor V Cambridge) and factor V Arg³⁰⁶→Gly mutations in venous thrombotic disease. Br J Haematol 1998; 103: 888-90.